What are the current clinical trials for Primary Progressive MS (PPMS)?
Research into PPMS treatments is actively growing, and there's genuine excitement in the MS community about what's in the pipeline. Here are some of the most promising areas being explored: Currently Approved Treatment
- Ocrelizumab (Ocrevus / Ocrevus Show Full Answer
What are the current clinical trials for Primary Progressive MS (PPMS)?
Research into PPMS treatments is actively growing, and there's genuine excitement in the MS community about what's in the pipeline. Here are some of the most promising areas being explored: Currently Approved Treatment
- Ocrelizumab (Ocrevus / Ocrevus Zunovo) — the only FDA-approved therapy for PPMS. It targets B cells to slow disability progression and has shown it may delay progression to wheelchair use by several years.
Emerging Therapies in Trials
- EBV-Specific T-Cell Therapy — A small Phase 1 trial showed clinical improvements in people with PPMS and was well-tolerated. More research is underway.
- High-Dose Biotin (MD1003) — Being studied as a potential remyelinating agent, meaning it may help rebuild the myelin that MS destroys. A Phase 3 trial has been conducted.
- Immunomodulatory drugs — New monoclonal antibody approaches beyond ocrelizumab are being explored.
- Stem Cell Therapy — Being investigated for its potential to repair damage to the central nervous system.
The best way to find trials you may qualify for is to speak with your neurologist or visit ClinicalTrials.gov, where you can search specifically for PPMS studies.
June 19
Join
Your Privacy Choices
